Cellceutix Corp (CTIX) 2.8200 $CTIX Cellceutix
Post# of 273396
Posted On: 07/29/2015 12:28:01 PM
Cellceutix Corp (CTIX) 2.8200 $CTIX
Cellceutix to begin clinical development programme of Brilacidin in ABSSSI patients upon successful End-of-Phase 2 Meeting with the US FDA
M2 - Tue Jul 21, 5:49AM CDT
Biopharmaceutical company Cellceutix (OtherOTC:CTIX) reported on Monday the receipt of the US Food and Drug Administration's (FDA) approval to advance brilacidin into phase 3 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics Pipeline Review, H1 2015 - 19 Companies & 31 Drug Profiles
M2 - Tue Jul 21, 3:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jqqgbl/vancomycinresista) has announced the addition of the "Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alchemia Limited - Alvogen, Inc. - Aphios Corporation - Cellceutix Corporation - Enanta Pharmaceuticals, Inc. - Helix BioMedix, Inc. - LegoChem Biosciences, Inc - Lytix Biopharma AS - MGB Biopharma Limited - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Nabriva Therapeutics AG - NovaBay Pharmaceuticals, Inc. - NovoBiotic Pharmaceuticals, LLC - Oragenics, Inc. - Sealife PHARMA GMBH - Sentinella Pharmaceuticals, Inc. - TAXIS Pharmaceuticals, Inc. - Wockhardt Limited Drug Profiles - auriclosene - brilacidin tetrahydrochloride - chrysophaentin - closthioamide - EDP-788 - Epimerox - HB-1345 - HT-01 - HT-02 - IBN-1 - LCB-010371 - LCB-010699 - lefamulin - LTX-109 - Marinus - MBX-1162 - MGBBP-3 - MRX-I - MU-1140 - NAI-107 - NAI-603 - SLP-0904 - SLP-0905 - Small Molecule for Bacterial Infections - Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections - Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - SP-2078 - Teixobactin - TXA-709 - WCK-4086 For more information visit http://www.researchandmarkets.com/research/jq...cinresista
ENTA: 47.38 (-0.67), OGEN: 2.20 (+0.46)
Cellceutix to Start Brilacidin Phase 3 Program in ABSSSI
Marketwired - Mon Jul 20, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has agreed to advancing brilacidin into phase 3 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Cellceutix's Kevetrin Receives FDA Orphan Drug Designation for the Treatment of Ovarian Cancer
Marketwired - Wed Jul 15, 12:15PM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration, or FDA, has granted Orphan Drug Designation to Kevetrin for the treatment of ovarian cancer.
Enterococcus Faecium Infections Pipeline Review 2015 - 25 Companies & 40 Drug Profiles
M2 - Fri Jul 10, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6pz9lr/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alchemia Limited - Alvogen, Inc. - Aphios Corporation - Cellceutix Corporation - ConjuGon, Inc. - ContraFect Corporation - Enanta Pharmaceuticals, Inc. - Helix BioMedix, Inc. - LegoChem Biosciences, Inc - Lytix Biopharma AS - Melinta Therapeutics, Inc - MGB Biopharma Limited - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Nabriva Therapeutics AG - NovaBay Pharmaceuticals, Inc. - Novan, Inc. - NovoBiotic Pharmaceuticals, LLC - Omnia Molecular Ltd. - Oragenics, Inc. - Sealife PHARMA GMBH - Sentinella Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - TAXIS Pharmaceuticals, Inc. - Wockhardt Limited Drug Profiles - auriclosene - brilacidin tetrahydrochloride - CF-304 - chrysophaentin - closthioamide - EDP-788 - Epimerox - GP-505 - HB-1345 - HT-01 - HT-02 - IBN-1 - LCB-010371 - LCB-010699 - lefamulin - LTX-109 - Marinus - MBX-1162 - MGBBP-3 - MRX-I - MU-1140 - NAI-107 - NAI-603 - NVN-1000 - NVN-4428 - RX-05 - RXP-873 - SLP-0904 - SLP-0905 - SM-295291 - SM-369926 For more information visit http://www.researchandmarkets.com/research/6p...terococcus
ENTA: 47.38 (-0.67), OGEN: 2.20 (+0.46)
Klebsiella Pneumoniae Infections Pipeline Review 2015 - 18 Companies & 34 Drug Profiles
M2 - Fri Jul 10, 2:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kbn3w/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - Cellceutix Corporation - Debiopharm International S.A. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Northern Antibiotics Oy - Nosopharm SAS - Novan, Inc. - Pfizer Inc. - Phico Therapeutics Ltd. - Sarepta Therapeutics, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Theraclone Sciences, Inc. - Trana Discovery, Inc. Drug Profiles - Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - BXN-112 - CB-027 - CB-618 - CC-1807 - CTIX-1278 - Debio-1454 - dusquetide - IBN-1 - Klebsiella pneumoniae vaccine - Monoclonal Antibodies for Klebsiella Pneumoniae Infections - Monoclonal Antibody for Klebsiella Pneumoniae Infections - MVX-506 - NAB-7061 - NAB-739 - NAB-741 - NOSO-95300 - NVN-1000 - NVN-4428 - PT-4 - RX-05 - RXP-792 - RXP-873 - S-649266 - Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections - SM-295291 - SM-369926 - Small Molecule for Gram-Negative Nosocomial Infections - Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Small Molecules to Inhibit DHFR for Infectious Diseases - TP-076 - TP-138 - TP-600 For more information visit http://www.researchandmarkets.com/research/4kbn3w/klebsiella
TTPH: 46.52 (-1.83), SRPT: 31.70 (-0.33), PFE: 35.67 (+0.32), MRK: 58.69 (+1.17)
Retinoblastoma - Pipeline Review, H1 2015 - 6 Companies & 7 Drug Profiles
M2 - Wed Jun 24, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cxghfl/retinoblastoma) has announced the addition of the "Retinoblastoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinoblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinoblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Cellceutix Corporation - Icon Bioscience, Inc. - Neotropix, Inc. - Recombio S.L - RXi Pharmaceuticals Corporation Drug Profiles - BL-8040 - Kevetrin - melphalan - NTX-010 - nutlin-3 - racotumomab - RNAi Oligonucleotide for Retinoblastoma For more information visit http://www.researchandmarkets.com/research/cx...noblastoma
Cellceutix's Fundamental Strength Outweighs Market Cap
Jim Bowie - at Seeking Alpha - Fri Jun 19, 10:36AM CDT
MRK: 58.69 (+1.17), AMGN: 171.50 (-1.24), ABBV: 71.31 (+0.08), NVS: 103.78 (+0.99)
Cellceutix Provides Update on Uplist Application
Marketwired - Mon Jun 08, 6:58AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today provided shareholders an update on the status of the Company's application to uplist to the NASDAQ exchange. Cellceutix last week learned that the application remains pending due to the price of CTIX stock currently below the minimum requirement.
Cellceutix Poster at ASCO 2015 Attracts Attention of Industry and Academia
Marketwired - Wed Jun 03, 8:27AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to provide shareholders insight to our presentation of certain clinical data at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago that concluded on Tuesday, June 2, 2015.
Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM For Oral Mucositis Expanding to Additional Centers
Marketwired - Mon Jun 01, 7:11AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that last week a second site opened enrollment in the Company's Phase 2 clinical trial of Brilacidin-OM for the prevention and treatment of oral mucositis in head and neck cancer patients undergoing chemoradiation. Clinical sites in Oregon and South Dakota are now enrolling patients to evaluate Brilacidin-OM for efficacy with additional sites to be added in June to keep the trial progressing in a timely manner.
Cellceutix to Present Poster on Kevetrin, a Novel p53 Targeted Therapy for Solid Tumors at American Society of Clinical Oncology (ASCO) Annual Meeting
Marketwired - Thu May 28, 6:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today announced that the Company will be sponsoring an abstract publication at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting being held May 29 - June 2, 2015 at McCormick Place in Chicago, Illinois. The poster will provide an overview of the Company's ongoing Phase 1 clinical trial of Kevetrin as a monotherapy for advanced solid tumors being conducted at Harvard Cancer Centers' Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center and will include information on the activation of p53 through inducing p21 gene expression. The poster will be presented during the poster session titled, "Developmental Therapeutics -- Clinical Pharmacology and Experimental Therapeutics" in S Hall A.
Enrollment Begins in Cellceutix Phase 2 Trial of Brilacidin-OM to Prevent Oral Mucositis in Patients Undergoing Chemoradiation
Marketwired - Tue May 26, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antibiotic applications, is pleased to announce that enrollment has commenced in the Company's Phase 2 clinical trial of Brilacidin-OM for the prevention and treatment of oral mucositis in patients undergoing chemoradiation for treatment of head and neck cancer.
Cellceutix to begin Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors in additional patients following IRB approval
M2 - Mon May 25, 5:49AM CDT
Biopharmaceutical company Cellceutix (OTC:CTIX) revealed on Friday that the Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors being conducted at Harvard University's Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center has been approved for additional patient enrollment.
IRB Approves Additional Enrollment in Cellceutix's Clinical Trial of New Cancer Drug Candidate for Solid Tumors
Marketwired - Fri May 22, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the Institutional Review Board ("IRB" overseeing the Company's Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors being conducted at Harvard University's Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center has approved the amended protocol to allow additional patient enrollment to the study.
Cellceutix Reports Results for Quarter Ended March 31, 2015; Enrollment for Oral Mucositis Studies to Begin This Month
Marketwired - Wed May 13, 6:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, today announced its financial results for the three months ended March 31, 2015. A detailed report of the third quarter fiscal 2015 has been filed in a Form 10-Q with the Securities and Exchange Commission.
Cellceutix Selects Independent Directors and Committee Members
Marketwired - Mon Apr 27, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce the selection of Dr. Barry Alan Schechter, Dr. Zorik Spektor and Mark Tobin as qualified independent directors and committee members of the Company's Board of Directors.
CellCeutix: Comparing Brilacidin With SoC Daptomycin
Kanak Kanti De - at Seeking Alpha - Tue Apr 21, 12:37PM CDT
Cellceutix Provides Corporate Update
Marketwired - Tue Apr 21, 9:06AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to provide shareholders with a comprehensive update on current corporate activity and pipeline development.
Cellceutix PIND Meeting Scheduled With FDA for Hidradenitis Suppurativa
Marketwired - Mon Apr 13, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted the Company's request for a Pre-Investigational New Drug (PIND) meeting to discuss the Company's plans for a Phase 2 clinical trial with one of the Company's Host Defense Proteins (HDPs) for the treatment of hidradenitis suppurativa. The meeting is scheduled during the third week of May.
Cellceutix to begin clinical development programme of Brilacidin in ABSSSI patients upon successful End-of-Phase 2 Meeting with the US FDA
M2 - Tue Jul 21, 5:49AM CDT
Biopharmaceutical company Cellceutix (OtherOTC:CTIX) reported on Monday the receipt of the US Food and Drug Administration's (FDA) approval to advance brilacidin into phase 3 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics Pipeline Review, H1 2015 - 19 Companies & 31 Drug Profiles
M2 - Tue Jul 21, 3:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jqqgbl/vancomycinresista) has announced the addition of the "Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alchemia Limited - Alvogen, Inc. - Aphios Corporation - Cellceutix Corporation - Enanta Pharmaceuticals, Inc. - Helix BioMedix, Inc. - LegoChem Biosciences, Inc - Lytix Biopharma AS - MGB Biopharma Limited - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Nabriva Therapeutics AG - NovaBay Pharmaceuticals, Inc. - NovoBiotic Pharmaceuticals, LLC - Oragenics, Inc. - Sealife PHARMA GMBH - Sentinella Pharmaceuticals, Inc. - TAXIS Pharmaceuticals, Inc. - Wockhardt Limited Drug Profiles - auriclosene - brilacidin tetrahydrochloride - chrysophaentin - closthioamide - EDP-788 - Epimerox - HB-1345 - HT-01 - HT-02 - IBN-1 - LCB-010371 - LCB-010699 - lefamulin - LTX-109 - Marinus - MBX-1162 - MGBBP-3 - MRX-I - MU-1140 - NAI-107 - NAI-603 - SLP-0904 - SLP-0905 - Small Molecule for Bacterial Infections - Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections - Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - SP-2078 - Teixobactin - TXA-709 - WCK-4086 For more information visit http://www.researchandmarkets.com/research/jq...cinresista
ENTA: 47.38 (-0.67), OGEN: 2.20 (+0.46)
Cellceutix to Start Brilacidin Phase 3 Program in ABSSSI
Marketwired - Mon Jul 20, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has agreed to advancing brilacidin into phase 3 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Cellceutix's Kevetrin Receives FDA Orphan Drug Designation for the Treatment of Ovarian Cancer
Marketwired - Wed Jul 15, 12:15PM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration, or FDA, has granted Orphan Drug Designation to Kevetrin for the treatment of ovarian cancer. Enterococcus Faecium Infections Pipeline Review 2015 - 25 Companies & 40 Drug Profiles
M2 - Fri Jul 10, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6pz9lr/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alchemia Limited - Alvogen, Inc. - Aphios Corporation - Cellceutix Corporation - ConjuGon, Inc. - ContraFect Corporation - Enanta Pharmaceuticals, Inc. - Helix BioMedix, Inc. - LegoChem Biosciences, Inc - Lytix Biopharma AS - Melinta Therapeutics, Inc - MGB Biopharma Limited - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Nabriva Therapeutics AG - NovaBay Pharmaceuticals, Inc. - Novan, Inc. - NovoBiotic Pharmaceuticals, LLC - Omnia Molecular Ltd. - Oragenics, Inc. - Sealife PHARMA GMBH - Sentinella Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - TAXIS Pharmaceuticals, Inc. - Wockhardt Limited Drug Profiles - auriclosene - brilacidin tetrahydrochloride - CF-304 - chrysophaentin - closthioamide - EDP-788 - Epimerox - GP-505 - HB-1345 - HT-01 - HT-02 - IBN-1 - LCB-010371 - LCB-010699 - lefamulin - LTX-109 - Marinus - MBX-1162 - MGBBP-3 - MRX-I - MU-1140 - NAI-107 - NAI-603 - NVN-1000 - NVN-4428 - RX-05 - RXP-873 - SLP-0904 - SLP-0905 - SM-295291 - SM-369926 For more information visit http://www.researchandmarkets.com/research/6p...terococcus
ENTA: 47.38 (-0.67), OGEN: 2.20 (+0.46)
Klebsiella Pneumoniae Infections Pipeline Review 2015 - 18 Companies & 34 Drug Profiles
M2 - Fri Jul 10, 2:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kbn3w/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - Cellceutix Corporation - Debiopharm International S.A. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Northern Antibiotics Oy - Nosopharm SAS - Novan, Inc. - Pfizer Inc. - Phico Therapeutics Ltd. - Sarepta Therapeutics, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Theraclone Sciences, Inc. - Trana Discovery, Inc. Drug Profiles - Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - BXN-112 - CB-027 - CB-618 - CC-1807 - CTIX-1278 - Debio-1454 - dusquetide - IBN-1 - Klebsiella pneumoniae vaccine - Monoclonal Antibodies for Klebsiella Pneumoniae Infections - Monoclonal Antibody for Klebsiella Pneumoniae Infections - MVX-506 - NAB-7061 - NAB-739 - NAB-741 - NOSO-95300 - NVN-1000 - NVN-4428 - PT-4 - RX-05 - RXP-792 - RXP-873 - S-649266 - Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections - SM-295291 - SM-369926 - Small Molecule for Gram-Negative Nosocomial Infections - Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Small Molecules to Inhibit DHFR for Infectious Diseases - TP-076 - TP-138 - TP-600 For more information visit http://www.researchandmarkets.com/research/4kbn3w/klebsiella
TTPH: 46.52 (-1.83), SRPT: 31.70 (-0.33), PFE: 35.67 (+0.32), MRK: 58.69 (+1.17)
Retinoblastoma - Pipeline Review, H1 2015 - 6 Companies & 7 Drug Profiles
M2 - Wed Jun 24, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cxghfl/retinoblastoma) has announced the addition of the "Retinoblastoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinoblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinoblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Cellceutix Corporation - Icon Bioscience, Inc. - Neotropix, Inc. - Recombio S.L - RXi Pharmaceuticals Corporation Drug Profiles - BL-8040 - Kevetrin - melphalan - NTX-010 - nutlin-3 - racotumomab - RNAi Oligonucleotide for Retinoblastoma For more information visit http://www.researchandmarkets.com/research/cx...noblastoma
Cellceutix's Fundamental Strength Outweighs Market Cap
Jim Bowie - at Seeking Alpha - Fri Jun 19, 10:36AM CDT
MRK: 58.69 (+1.17), AMGN: 171.50 (-1.24), ABBV: 71.31 (+0.08), NVS: 103.78 (+0.99)
Cellceutix Provides Update on Uplist Application
Marketwired - Mon Jun 08, 6:58AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today provided shareholders an update on the status of the Company's application to uplist to the NASDAQ exchange. Cellceutix last week learned that the application remains pending due to the price of CTIX stock currently below the minimum requirement. Cellceutix Poster at ASCO 2015 Attracts Attention of Industry and Academia
Marketwired - Wed Jun 03, 8:27AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to provide shareholders insight to our presentation of certain clinical data at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago that concluded on Tuesday, June 2, 2015. Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM For Oral Mucositis Expanding to Additional Centers
Marketwired - Mon Jun 01, 7:11AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that last week a second site opened enrollment in the Company's Phase 2 clinical trial of Brilacidin-OM for the prevention and treatment of oral mucositis in head and neck cancer patients undergoing chemoradiation. Clinical sites in Oregon and South Dakota are now enrolling patients to evaluate Brilacidin-OM for efficacy with additional sites to be added in June to keep the trial progressing in a timely manner. Cellceutix to Present Poster on Kevetrin, a Novel p53 Targeted Therapy for Solid Tumors at American Society of Clinical Oncology (ASCO) Annual Meeting
Marketwired - Thu May 28, 6:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today announced that the Company will be sponsoring an abstract publication at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting being held May 29 - June 2, 2015 at McCormick Place in Chicago, Illinois. The poster will provide an overview of the Company's ongoing Phase 1 clinical trial of Kevetrin as a monotherapy for advanced solid tumors being conducted at Harvard Cancer Centers' Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center and will include information on the activation of p53 through inducing p21 gene expression. The poster will be presented during the poster session titled, "Developmental Therapeutics -- Clinical Pharmacology and Experimental Therapeutics" in S Hall A. Enrollment Begins in Cellceutix Phase 2 Trial of Brilacidin-OM to Prevent Oral Mucositis in Patients Undergoing Chemoradiation
Marketwired - Tue May 26, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antibiotic applications, is pleased to announce that enrollment has commenced in the Company's Phase 2 clinical trial of Brilacidin-OM for the prevention and treatment of oral mucositis in patients undergoing chemoradiation for treatment of head and neck cancer. Cellceutix to begin Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors in additional patients following IRB approval
M2 - Mon May 25, 5:49AM CDT
Biopharmaceutical company Cellceutix (OTC:CTIX) revealed on Friday that the Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors being conducted at Harvard University's Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center has been approved for additional patient enrollment.
IRB Approves Additional Enrollment in Cellceutix's Clinical Trial of New Cancer Drug Candidate for Solid Tumors
Marketwired - Fri May 22, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the Institutional Review Board ("IRB" overseeing the Company's Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors being conducted at Harvard University's Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center has approved the amended protocol to allow additional patient enrollment to the study. Cellceutix Reports Results for Quarter Ended March 31, 2015; Enrollment for Oral Mucositis Studies to Begin This Month
Marketwired - Wed May 13, 6:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, today announced its financial results for the three months ended March 31, 2015. A detailed report of the third quarter fiscal 2015 has been filed in a Form 10-Q with the Securities and Exchange Commission. Cellceutix Selects Independent Directors and Committee Members
Marketwired - Mon Apr 27, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce the selection of Dr. Barry Alan Schechter, Dr. Zorik Spektor and Mark Tobin as qualified independent directors and committee members of the Company's Board of Directors. CellCeutix: Comparing Brilacidin With SoC Daptomycin
Kanak Kanti De - at Seeking Alpha - Tue Apr 21, 12:37PM CDT
Cellceutix Provides Corporate Update
Marketwired - Tue Apr 21, 9:06AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to provide shareholders with a comprehensive update on current corporate activity and pipeline development. Cellceutix PIND Meeting Scheduled With FDA for Hidradenitis Suppurativa
Marketwired - Mon Apr 13, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted the Company's request for a Pre-Investigational New Drug (PIND) meeting to discuss the Company's plans for a Phase 2 clinical trial with one of the Company's Host Defense Proteins (HDPs) for the treatment of hidradenitis suppurativa. The meeting is scheduled during the third week of May. 
(0)
(0)